---
title: "\"Performance\" HAOHAI BIOTEC earned 305 million RMB in the first three quarters, a decline of 10.6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262771353.md"
description: "HAOHAI BIOTEC announced its third-quarter report for the period ending in September, achieving operating revenue of 1.899 billion RMB (same below) according to Chinese accounting standards, a year-on-year decrease of 8.5%. The net profit attributable to shareholders was 305 million RMB, a decline of 10.6%, with earnings per share of 1.31 RMB"
datetime: "2025-10-26T10:51:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262771353.md)
  - [en](https://longbridge.com/en/news/262771353.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262771353.md)
generator: "portal-rs"
---

# "Performance" HAOHAI BIOTEC earned 305 million RMB in the first three quarters, a decline of 10.6%

HAOHAI BIOTEC (06826.HK) announced its third-quarter report for the period ending in September, achieving operating revenue of 1.899 billion RMB (the same below), a year-on-year decrease of 8.5%. The net profit attributable to shareholders was 305 million RMB, a decline of 10.6%, with earnings per share of 1.31 RMB

### Related Stocks

- [688366.CN](https://longbridge.com/en/quote/688366.CN.md)
- [06826.HK](https://longbridge.com/en/quote/06826.HK.md)

## Related News & Research

- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [18:23 ETAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/296541925.md)
- [Simcere Pharmaceutical Details Board and Committee Structure](https://longbridge.com/en/news/296529910.md)
- [WellSpan and Johns Hopkins renew partnership for advanced cancer care access](https://longbridge.com/en/news/296596329.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**